GENB · Generate Biomedicines, Inc.
$13.40
-0.43 (-3.11%)
At close · Jul 24
Going-concern doubt
— cleared May 7, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company's current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at March 31, 2026, it expects to have sufficient cash to support current operating plans into the first half of 2028.”View the 10-Q filed May 7, 2026
Market Cap
$1.77B
Shares
128.19M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-06-29 | 2,355 | $16.47 | $38,787 |
| 2026-06-25 | 10 | $16.23 | $162 |
| 2026-06-24 | 7,715 | $15.43 | $119,042 |
| 2026-06-22 | 9,074 | $14.49 | $131,482 |
| 2026-06-17 | 171 | $13.37 | $2,286 |
| 2026-06-15 | 27,590 | $12.38 | $341,564 |
| 2026-06-08 | 4,005 | $12.87 | $51,544 |
| 2026-06-04 | 13,520 | $12.91 | $174,543 |
| 2026-06-03 | 4,253 | $11.97 | $50,908 |
| 2026-05-26 | 512 | $14.53 | $7,439 |
| 2026-05-21 | 85,052 | $13.02 | $1,107,377 |
| 2026-05-19 | 600 | $13.01 | $7,806 |
| 2026-05-18 | 4,202 | $16.00 | $67,232 |
| 2026-04-27 | 6,348 | $12.80 | $81,254 |
Showing 1–14 of 14 settlements